Thibault Boutherin
Stock Analyst at Morgan Stanley
(3.42)
# 2,274
Out of 4,455 analysts
161
Total ratings
57.4%
Success rate
5.9%
Average return
Main Sectors:
Stocks Rated by Thibault Boutherin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Maintained: Buy | CHF 135.00 | $126.28 | +6.91% | 13 | Jun 25, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 270.00 → kr 250.00 | $316.16 | -20.93% | 6 | May 7, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Hold | CHF 155.00 → CHF 160.00 | $178.25 | -10.24% | 9 | Apr 27, 2026 | |
| NVS Novartis AG | Maintained: Buy | $143 → $170 | $155.41 | +9.39% | 3 | Mar 26, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €40.00 → €53.00 | $47.00 | +12.77% | 5 | Mar 11, 2026 | |
| BME: GRF Grifols, S.A. | Downgraded: Hold | €12.00 → €11.00 | $9.13 | +20.53% | 7 | Mar 10, 2026 | |
| NVO Novo Nordisk | Upgraded: Hold | $42 → $40 | $48.07 | -16.79% | 5 | Mar 3, 2026 | |
| INDV Indivior Pharmaceuticals | Maintained: Buy | $28 → $36 | $41.83 | -13.94% | 11 | Dec 3, 2025 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 → €135.00 | $145.65 | -7.31% | 5 | Dec 3, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 650.00 | $534.60 | +21.59% | 10 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $10 | $3.68 | +171.74% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 38.00 → CHF 50.00 | $71.88 | -30.44% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €300.00 | $224.00 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €250.00 | $175.20 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €715.00 | $785.40 | n/a | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 2,100p → 2,400p | $1,531.00 | n/a | 15 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 | $2.74 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €12.00 | $4.91 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 912p | $1,284.50 | n/a | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 | $162.40 | n/a | 18 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $37 → $39 | $88.69 | n/a | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | CHF 4.00 → CHF 1.00 | $6.86 | n/a | 11 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €0.87 → €105.00 | $257.33 | n/a | 12 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 | $7.39 | n/a | 4 | Dec 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €11.50 → €11.00 | $11.28 | n/a | 5 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $33.21 | n/a | 2 | Oct 4, 2023 |
Novartis AG
Jun 25, 2026
Maintained: Buy
Price Target: CHF 135.00
Current: $126.28
Upside: +6.91%
Novo Nordisk A/S
May 7, 2026
Maintained: Hold
Price Target: kr 270.00 → kr 250.00
Current: $316.16
Upside: -20.93%
Galderma Group AG
Apr 27, 2026
Maintained: Hold
Price Target: CHF 155.00 → CHF 160.00
Current: $178.25
Upside: -10.24%
Novartis AG
Mar 26, 2026
Maintained: Buy
Price Target: $143 → $170
Current: $155.41
Upside: +9.39%
Bayer Aktiengesellschaft
Mar 11, 2026
Maintained: Buy
Price Target: €40.00 → €53.00
Current: $47.00
Upside: +12.77%
Grifols, S.A.
Mar 10, 2026
Downgraded: Hold
Price Target: €12.00 → €11.00
Current: $9.13
Upside: +20.53%
Novo Nordisk
Mar 3, 2026
Upgraded: Hold
Price Target: $42 → $40
Current: $48.07
Upside: -16.79%
Indivior Pharmaceuticals
Dec 3, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $41.83
Upside: -13.94%
Merck KGaA
Dec 3, 2025
Maintained: Hold
Price Target: €130.00 → €135.00
Current: $145.65
Upside: -7.31%
Lonza Group AG
Dec 3, 2025
Maintained: Buy
Price Target: CHF 650.00
Current: $534.60
Upside: +21.59%
Dec 3, 2025
Maintained: Buy
Price Target: $14 → $10
Current: $3.68
Upside: +171.74%
Dec 3, 2025
Maintained: Hold
Price Target: CHF 38.00 → CHF 50.00
Current: $71.88
Upside: -30.44%
Apr 22, 2025
Maintained: Buy
Price Target: €300.00
Current: $224.00
Upside: n/a
Apr 22, 2025
Maintained: Buy
Price Target: €250.00
Current: $175.20
Upside: n/a
Mar 5, 2025
Maintained: Buy
Price Target: €715.00
Current: $785.40
Upside: n/a
Feb 12, 2025
Maintained: Hold
Price Target: 2,100p → 2,400p
Current: $1,531.00
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: $14
Current: $2.74
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: €12.00
Current: $4.91
Upside: n/a
Jul 15, 2024
Maintained: Buy
Price Target: 912p
Current: $1,284.50
Upside: n/a
May 15, 2024
Maintained: Hold
Price Target: €120.00
Current: $162.40
Upside: n/a
May 8, 2024
Maintained: Hold
Price Target: $37 → $39
Current: $88.69
Upside: n/a
Apr 3, 2024
Maintained: Sell
Price Target: CHF 4.00 → CHF 1.00
Current: $6.86
Upside: n/a
Mar 25, 2024
Upgraded: Hold
Price Target: €0.87 → €105.00
Current: $257.33
Upside: n/a
Dec 29, 2023
Maintained: Hold
Price Target: $16
Current: $7.39
Upside: n/a
Nov 13, 2023
Maintained: Hold
Price Target: €11.50 → €11.00
Current: $11.28
Upside: n/a
Oct 4, 2023
Maintained: Hold
Price Target: $10
Current: $33.21
Upside: n/a